241 related articles for article (PubMed ID: 10843171)
1. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
Fogelman I; Ribot C; Smith R; Ethgen D; Sod E; Reginster JY
J Clin Endocrinol Metab; 2000 May; 85(5):1895-900. PubMed ID: 10843171
[TBL] [Abstract][Full Text] [Related]
2. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.
Mortensen L; Charles P; Bekker PJ; Digennaro J; Johnston CC
J Clin Endocrinol Metab; 1998 Feb; 83(2):396-402. PubMed ID: 9467547
[TBL] [Abstract][Full Text] [Related]
3. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
[TBL] [Abstract][Full Text] [Related]
4. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
Hooper MJ; Ebeling PR; Roberts AP; Graham JJ; Nicholson GC; D'Emden M; Ernst TF; Wenderoth D
Climacteric; 2005 Sep; 8(3):251-62. PubMed ID: 16390757
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.
Delmas PD; Balena R; Confravreux E; Hardouin C; Hardy P; Bremond A
J Clin Oncol; 1997 Mar; 15(3):955-62. PubMed ID: 9060533
[TBL] [Abstract][Full Text] [Related]
6. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
[TBL] [Abstract][Full Text] [Related]
7. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.
Bonnick S; Saag KG; Kiel DP; McClung M; Hochberg M; Burnett SM; Sebba A; Kagan R; Chen E; Thompson DE; de Papp AE
J Clin Endocrinol Metab; 2006 Jul; 91(7):2631-7. PubMed ID: 16636120
[TBL] [Abstract][Full Text] [Related]
8. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
Välimäki MJ; Farrerons-Minguella J; Halse J; Kröger H; Maroni M; Mulder H; Muñoz-Torres M; Sääf M; Snorre Øfjord E
Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
[TBL] [Abstract][Full Text] [Related]
9. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Cohen S; Levy RM; Keller M; Boling E; Emkey RD; Greenwald M; Zizic TM; Wallach S; Sewell KL; Lukert BP; Axelrod DW; Chines AA
Arthritis Rheum; 1999 Nov; 42(11):2309-18. PubMed ID: 10555025
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
Brown JP; Kendler DL; McClung MR; Emkey RD; Adachi JD; Bolognese MA; Li Z; Balske A; Lindsay R
Calcif Tissue Int; 2002 Aug; 71(2):103-11. PubMed ID: 12085156
[TBL] [Abstract][Full Text] [Related]
11. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
Boonen S; Lorenc RS; Wenderoth D; Stoner KJ; Eusebio R; Orwoll ES
Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
[TBL] [Abstract][Full Text] [Related]
12. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.
Harris ST; Eriksen EF; Davidson M; Ettinger MP; Moffett AH; Baylink DJ; Crusan CE; Chines AA
J Clin Endocrinol Metab; 2001 May; 86(5):1890-7. PubMed ID: 11344179
[TBL] [Abstract][Full Text] [Related]
13. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.
Clemmesen B; Ravn P; Zegels B; Taquet AN; Christiansen C; Reginster JY
Osteoporos Int; 1997; 7(5):488-95. PubMed ID: 9425508
[TBL] [Abstract][Full Text] [Related]
14. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Weryha G; Marques-Neto JF; Gaines KA; Verbruggen N; Melton ME
Clin Drug Investig; 2006; 26(2):63-74. PubMed ID: 17163237
[TBL] [Abstract][Full Text] [Related]
15. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
16. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients.
Eastell R; Devogelaer JP; Peel NF; Chines AA; Bax DE; Sacco-Gibson N; Nagant de Deuxchaisnes C; Russell RG
Osteoporos Int; 2000; 11(4):331-7. PubMed ID: 10928223
[TBL] [Abstract][Full Text] [Related]
17. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
Sebba AI; Bonnick SL; Kagan R; Thompson DE; Skalky CS; Chen E; de Papp AE;
Curr Med Res Opin; 2004 Dec; 20(12):2031-41. PubMed ID: 15706659
[TBL] [Abstract][Full Text] [Related]
18. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
Hosking D; Adami S; Felsenberg D; Andia JC; Välimäki M; Benhamou L; Reginster JY; Yacik C; Rybak-Feglin A; Petruschke RA; Zaru L; Santora AC
Curr Med Res Opin; 2003; 19(5):383-94. PubMed ID: 13678475
[TBL] [Abstract][Full Text] [Related]
19. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
Reid DM; Adami S; Devogelaer JP; Chines AA
Calcif Tissue Int; 2001 Oct; 69(4):242-7. PubMed ID: 11730260
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
Palomba S; Orio F; Manguso F; Falbo A; Russo T; Tolino A; Tauchmanovà L; Colao A; Doldo P; Mastrantonio P; Zullo F
Osteoporos Int; 2005 Sep; 16(9):1141-9. PubMed ID: 15928801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
